

Summary of Business Results for the Third Quarter Ended September 30, 2017 [Japan GAAP] (Consolidated)

November 10, 2017

Company **tella, Inc.**
 Stock Code 2191
 Representative Yuichiro Yazaki, President, CEO
 Contact Shogo Kozuka, Director, CFO
 Expected date of filing of quarterly report: November 10, 2017
 Preparation of quarterly supplementary financial document: None
 Quarterly results briefing: None

Listed on the TSE
 URL: <http://www.tella.jp>

T E L: +81-3-5937-2111
 Expected starting date of dividend payment: -

(Rounded down to million yen)

1. Consolidated business results for the nine months ended September 2017 (January 1, 2017 through September 30, 2017)

(1) Consolidated results of operations (% change from the previous corresponding period)

	Net sales		Operating income		Ordinary income		Net income attributable to owners of parent	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Nine months ended Sep. 2017	842	-40.7	-201	-	-230	-	-606	-
Nine months ended Sep. 2016	1,421	-3.9	-368	-	-390	-	-463	-

(Note) Comprehensive income

Nine months ended September 2017: -601 million yen (-%)

Nine months ended September 2016: -445 million yen (-%)

	Net income per share		Diluted net income per share	
	Yen	Yen	Yen	Yen
Nine months ended Sep. 2017	-39.52	-	-	-
Nine months ended Sep. 2016	-33.12	-	-	-

(2) Consolidated financial position

	Total assets	Net assets	Shareholders' equity ratio
	Million yen	Million yen	%
As of Sep. 2017	1,911	1,381	72.1
As of Dec. 2016	1,537	609	33.5

(Reference) Shareholders' equity

As of September 2017: 1,378 million yen

As of December 2016: 515 million yen

2. Dividends

	Annual dividend				
	End of 1Q	End of 2Q	End of 3Q	Year-end	Total
Year ended Dec. 2016	-	0.00	-	0.00	0.00
Year ending Dec. 2017	-	0.00	-	-	-
Year ending Dec. 2017(forecast)	-	-	-	0.00	0.00

(Note) Revisions to dividend forecast for the current quarter: None

3. Forecast of consolidated business results for the fiscal year ending December 2017

(January 1, 2017 through December 31, 2017) (% change from the previous corresponding period)

	Net sales		Operating income		Ordinary income		Net income attributable to owners of parent		Net income per share	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen	
Year ending Dec. 2017	950	-30.7	-200	-	-230	-	-600	-	-39.07	

(Note) Revisions to business forecast for the current quarter: None

※Notes

(1) Changes in significant subsidiaries during the period (changes in specified subsidiaries accompanying changes in the scope of consolidation): Yes
Excluded:1 (Company name) BIOMEDICA SOLUTION, LTD.

(2) Application of accounting procedures specific to preparation of the consolidated quarterly financial statements:
None

(3) Changes in accounting policies, accounting estimates and restatement

- | | |
|---|--------|
| ①Changes in accounting policies associated with revision of accounting standards: | : None |
| ②Changes in accounting policies other than ① | : None |
| ③Changes in accounting estimates | : None |
| ④Restatement | : None |

(4) Shares outstanding (common stock)

- | | |
|---|-------------------|
| ① Number of shares outstanding at the end of period (treasury stock included) | |
| As of June 2017 | 16,999,156 shares |
| As of December 2016 | 13,995,156 shares |
| ② Treasury stock at the end of period | |
| As of June 2017 | 253 shares |
| As of December 2016 | 253 shares |
| ③ Average number of stock during period (quarterly cumulative period) | |
| Six months ended June 2017 | 15,356,976 shares |
| Six months ended June 2016 | 13,994,903 shares |

***Quarterly financial summary is not subject to the quarterly review procedures**

***Explanation regarding appropriate use of business forecasts and other special instructions**

Forecasts regarding future performance in this material are based on information currently available to the Company and certain assumptions that the Company deems to be reasonable at the time this report was prepared. Actual results may differ significantly from the forecasts due to various factors.